Migraine Australia is monitoring the shortage of IV fluids which is impacting the ability of some people to access care.
Manufacturing issues and unexpected increases in demand are behind a global shortage of IV fluids. This shortage is likely to continue through until the end of 2024, according to the Therapeutic Goods Administration.
There are confusing reports, claims and counter claims across the country which is understandably upsetting and confusing for those who rely on IV fluids for their treatment.
The most significant need for IV fluids by migraine patients is:
- In the administration of Vyepti, a CGRP monoclonal antibody preventative treatment administered as an infusion in 100ml of sodium chloride.
- In emergency, where fluids are commonly given to relieve acute migraine attack, and for the administration of IV medications like anti-emetics and chlorpromazine (Largactil).
- In the administration of other infusions prescribed for those with particularly challenging migraine, such as IV infusions of ketamine.
Migraine Australia has received some reports of people not getting IV fluids as they normally would when presenting to emergency, and being warned that their Vyepti infusions may be cancelled or delayed. Meanwhile, others have had their infusions this week with no problem.
We have already been in touch with Lundbeck, the drug company that makes Vyepti on this issue. There advice is as follows:
"Lundbeck Australia is concerned about the current shortage of IV fluids in Australia and its potential effect on migraine patients. We are closely monitoring the situation and have reached out to neurologists, an infusion provider and our advisory board to obtain their insights and advice.
Patients with concerns are encouraged to speak to their treating neurologist about their continued treatment. "
We are monitoring the situation, and if it becomes necessary, will be clearly communicating that it is not ok for migraine patients to be denied their essential treatment so that hospitals can conserve IV fluids for patients they consider more worthy. While the decision of who gets treatment and who does not in the face of supply shortages is always an awful one we wish on no health professional, we must continue to call out the ever-present stigma against migraine that exists in our health system and oppose any misinformed decisions to deny care, particularly Vyepti infusions that must be delivered on time.